Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Upstream Bio, Inc. (UPB)

Upstream Bio Q3 net loss widens to $41.2 million; Phase 3 trials planned for Q1 2027

Negative Impact 3 of 5 earnings

Upstream Bio reported a third-quarter 2026 net loss of $41.2 million, up from $33.7 million a year earlier, as research and development and general and administrative expenses rose and collaboration revenue fell to $395,000 from $683,000. The company had $207.4 million in cash, cash equivalents and short-term investments at September 30, 2026, which it expects to fund planned operations through 2027, and it plans to start Phase 3 trials of verekitug in severe asthma and CRSwNP in the first quarter of 2027.

Key points

  • Q3 2026 net loss was $41.2 million, compared with $33.7 million in Q3 2025.
  • Research and development expenses were $36.6 million, up $3.6 million from $33.0 million a year earlier.
  • General and administrative expenses were $7.2 million, up $1.7 million from $5.5 million.
  • Cash, cash equivalents and short-term investments totaled $207.4 million as of September 30, 2026.

The filing

CompanyUpstream Bio, Inc. (UPB)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:05 AM ET
Accession number0001193125-26-454405

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:11 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.